Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXDX NASDAQ:EYPT NASDAQ:PACB NASDAQ:QTRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXDXAccelerate Diagnostics$0.03$0.65$0.03▼$0.59$857K0.226.48 million shsN/AEYPTEyepoint Pharmaceuticals$12.93+1.2%$13.46$5.45▼$19.11$1.07B1.76807,220 shs783,848 shsPACBPacific Biosciences of California$1.22-2.4%$1.42$0.85▼$2.73$388.25M2.46.39 million shs4.63 million shsQTRXQuanterix$2.69+1.9%$3.44$2.39▼$8.77$124.36M1.151.49 million shs814,980 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXDXAccelerate Diagnostics0.00%0.00%0.00%0.00%-16.05%EYPTEyepoint Pharmaceuticals+2.24%-3.47%-9.43%-16.63%+117.72%PACBPacific Biosciences of California+5.04%+3.31%-27.75%-22.36%+27.40%QTRXQuanterix+4.76%-4.69%-18.01%-54.17%-45.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXDXAccelerate Diagnostics$0.03$0.65$0.03▼$0.59$857K0.226.48 million shsN/AEYPTEyepoint Pharmaceuticals$12.93+1.2%$13.46$5.45▼$19.11$1.07B1.76807,220 shs783,848 shsPACBPacific Biosciences of California$1.22-2.4%$1.42$0.85▼$2.73$388.25M2.46.39 million shs4.63 million shsQTRXQuanterix$2.69+1.9%$3.44$2.39▼$8.77$124.36M1.151.49 million shs814,980 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXDXAccelerate Diagnostics0.00%0.00%0.00%0.00%-16.05%EYPTEyepoint Pharmaceuticals+2.24%-3.47%-9.43%-16.63%+117.72%PACBPacific Biosciences of California+5.04%+3.31%-27.75%-22.36%+27.40%QTRXQuanterix+4.76%-4.69%-18.01%-54.17%-45.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXDXAccelerate Diagnostics 0.00N/AN/AN/AEYPTEyepoint Pharmaceuticals 3.00Buy$31.80145.94% UpsidePACBPacific Biosciences of California 1.80Reduce$1.8350.27% UpsideQTRXQuanterix 1.67Reduce$4.0048.70% UpsideCurrent Analyst Ratings BreakdownLatest QTRX, AXDX, PACB, and EYPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026QTRXQuanterix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026PACBPacific Biosciences of California BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$1.00 ➝ $1.505/7/2026EYPTEyepoint Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$39.00 ➝ $37.005/7/2026QTRXQuanterix TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$7.00 ➝ $4.004/21/2026EYPTEyepoint Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PACBPacific Biosciences of California Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026QTRXQuanterix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026QTRXQuanterix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$8.00 ➝ $4.004/20/2026PACBPacific Biosciences of California Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/14/2026PACBPacific Biosciences of California BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderweight$1.50 ➝ $1.003/9/2026EYPTEyepoint Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $35.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXDXAccelerate Diagnostics$11.70M0.07N/AN/A($1.37) per share-0.02EYPTEyepoint Pharmaceuticals$31.37M34.56N/AN/A$2.75 per share4.70PACBPacific Biosciences of California$160.01M2.37$0.77 per share1.58$0.01 per share122.00QTRXQuanterix$138.90M0.91N/AN/A$5.99 per share0.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXDXAccelerate Diagnostics-$61.62M-$2.34N/AN/AN/A-471.83%N/A-191.66%N/AEYPTEyepoint Pharmaceuticals-$231.96M-$3.50N/AN/AN/A-3,566.63%-110.54%-90.15%8/5/2026 (Estimated)PACBPacific Biosciences of California-$546.38M-$0.43N/AN/AN/A-80.35%-571.06%-18.82%8/3/2026 (Estimated)QTRXQuanterix-$107.15M-$2.36N/AN/AN/A-71.86%-23.92%-17.66%8/6/2026 (Estimated)Latest QTRX, AXDX, PACB, and EYPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PACBPacific Biosciences of California-$0.17-$0.12+$0.05-$0.03$39.94 million$37.18 million5/6/2026Q1 2026EYPTEyepoint Pharmaceuticals-$0.79-$0.99-$0.20-$0.99$0.35 million$0.70 million5/6/2026Q1 2026QTRXQuanterix-$0.5133-$0.39+$0.1233-$0.37$36.84 million$35.90 million3/4/2026Q4 2025EYPTEyepoint Pharmaceuticals-$0.78-$0.8143-$0.0343-$0.81$1.01 million$0.62 million3/2/2026Q4 2025QTRXQuanterix-$0.27-$0.38-$0.11-$0.49$37.95 million$41.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXDXAccelerate DiagnosticsN/AN/AN/AN/AN/AEYPTEyepoint PharmaceuticalsN/AN/AN/AN/AN/APACBPacific Biosciences of CaliforniaN/AN/AN/AN/AN/AQTRXQuanterixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXDXAccelerate DiagnosticsN/A1.501.34EYPTEyepoint PharmaceuticalsN/A6.666.63PACBPacific Biosciences of CaliforniaN/A5.654.87QTRXQuanterixN/A3.722.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXDXAccelerate Diagnostics17.14%EYPTEyepoint Pharmaceuticals99.41%PACBPacific Biosciences of CaliforniaN/AQTRXQuanterix86.48%Insider OwnershipCompanyInsider OwnershipAXDXAccelerate Diagnostics43.60%EYPTEyepoint Pharmaceuticals4.46%PACBPacific Biosciences of California2.50%QTRXQuanterix1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXDXAccelerate Diagnostics22025.21 million14.13 millionNo DataEYPTEyepoint Pharmaceuticals12083.84 million80.10 millionOptionablePACBPacific Biosciences of California730310.60 million302.84 millionOptionableQTRXQuanterix46047.11 million46.40 millionOptionableQTRX, AXDX, PACB, and EYPT HeadlinesRecent News About These CompaniesWhy Quanterix Corporation’s (QTRX) Stock Is Down 7.64%May 19 at 11:46 PM | aaii.comACanaccord Genuity Reaffirms Their Hold Rating on Quanterix (QTRX)May 14, 2026 | theglobeandmail.comQuanterix (QTRX) price target decreased by 33.33% to 4.42May 14, 2026 | msn.comQuanterix Corp.May 13, 2026 | marketwatch.comQuanterix Announces Planned Transition of Chief Financial OfficerMay 12, 2026 | businesswire.comQuanterix (NASDAQ:QTRX) Stock Rating Upgraded by Wall Street ZenMay 9, 2026 | marketbeat.comQuanterix (NASDAQ:QTRX) Announces Earnings ResultsMay 8, 2026 | marketbeat.comQuanterix Corporation (QTRX) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comQuanterix Releases Financial Results for the First Quarter of 2026May 8, 2026 | finance.yahoo.comQuanterix (QTRX) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comTD Cowen Has Lowered Expectations for Quanterix (NASDAQ:QTRX) Stock PriceMay 7, 2026 | marketbeat.comQuanterix Q1 Earnings Call HighlightsMay 6, 2026 | marketbeat.comQuanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comLucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical WorkflowsMay 6, 2026 | timesargus.comTHow The Quanterix (QTRX) Story Is Shifting After The Latest Fair Value ResetMay 3, 2026 | finance.yahoo.comQuanterix (QTRX) Expected to Announce Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comQuanterix (QTRX) price target decreased by 13.33% to 6.63April 28, 2026 | msn.comQuanterix To Report First Quarter 2026 Financial Results on May 6, 2026April 24, 2026 | businesswire.comAidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical OncologyApril 17, 2026 | businesswire.comQuanterix Debuts Content Innovation Engine at AACR 2026April 15, 2026 | businesswire.comQuanterix Corporation Announces Date of 2026 Annual MeetingMarch 27, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQTRX, AXDX, PACB, and EYPT Company DescriptionsAccelerate Diagnostics NASDAQ:AXDXAccelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.Eyepoint Pharmaceuticals NASDAQ:EYPT$12.93 +0.15 (+1.17%) Closing price 04:00 PM EasternExtended Trading$12.92 -0.01 (-0.08%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Pacific Biosciences of California NASDAQ:PACB$1.22 -0.03 (-2.40%) Closing price 04:00 PM EasternExtended Trading$1.23 +0.01 (+0.82%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.Quanterix NASDAQ:QTRX$2.69 +0.05 (+1.89%) Closing price 04:00 PM EasternExtended Trading$2.76 +0.07 (+2.57%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
